Carisma Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $20.9K
- Price
- $0.0005
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 8.6K
About
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Quick stats
Shares outstanding41.8M
Computed float20.4M
Float / shares48.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001485003
Websitehttps://www.carismatx.com
AI Summary
AI-generated1/14
minorneutralother
CARMILA: Information Concerning the Total Number of Voting Rights and Share
Carmila disclosed its share capital structure as of 30 September 2026 in a routine regulatory filing.
The company reported 139,616,607 issued shares, with 138,525,641 real voting rights excluding treasury shares and 139,616,607 theoretical voting rights including them.
The disclosure is made under French Commercial Code and AMF requirements and contains no new corporate or financial information.